See more : Chaoda Modern Agriculture (Holdings) Limited (CMGHY) Income Statement Analysis – Financial Results
Complete financial analysis of Microbix Biosystems Inc. (MBXBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Microbix Biosystems Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Arcane Crypto AB (ARCANE.ST) Income Statement Analysis – Financial Results
- Sumitomo Electric Industries, Ltd. (SMTOY) Income Statement Analysis – Financial Results
- Techno Electric & Engineering Company Limited (TECHNOE.NS) Income Statement Analysis – Financial Results
- iQ International AG (IQL.DE) Income Statement Analysis – Financial Results
- Gillette India Limited (GILLETTE.NS) Income Statement Analysis – Financial Results
Microbix Biosystems Inc. (MBXBF)
About Microbix Biosystems Inc.
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.51M | 19.08M | 18.59M | 10.52M | 13.41M | 12.51M | 10.19M | 9.52M | 8.87M | 8.40M | 7.57M | 6.67M | 6.23M | 6.46M | 6.08M | 4.99M | 4.05M | 3.64M | 4.38M | 4.07M | 2.85M | 2.81M | 2.99M | 1.86M | 1.60M | 3.10M | 2.70M |
| Cost of Revenue | 9.03M | 7.95M | 7.55M | 5.86M | 6.86M | 7.14M | 5.37M | 4.54M | 3.03M | 3.89M | 3.74M | 3.91M | 3.24M | 2.73M | 2.52M | 2.48M | 2.12M | 1.75M | 1.68M | 1.49M | 1.02M | 835.27K | 949.84K | 577.27K | 600.00K | 600.00K | 500.00K |
| Gross Profit | 7.48M | 11.12M | 11.04M | 4.66M | 6.55M | 5.37M | 4.81M | 4.98M | 5.84M | 4.51M | 3.83M | 2.75M | 2.98M | 3.73M | 3.56M | 2.51M | 1.93M | 1.89M | 2.70M | 2.58M | 1.82M | 1.97M | 2.04M | 1.28M | 1.00M | 2.50M | 2.20M |
| Gross Profit Ratio | 45.30% | 58.32% | 59.40% | 44.28% | 48.82% | 42.92% | 47.25% | 52.33% | 65.81% | 53.73% | 50.62% | 41.30% | 47.92% | 57.78% | 58.60% | 50.36% | 47.74% | 51.94% | 61.72% | 63.36% | 64.03% | 70.24% | 68.22% | 68.91% | 62.50% | 80.65% | 81.48% |
| Research & Development | 2.05M | 1.80M | 1.03M | 1.01M | 1.04M | 1.09M | 994.58K | 493.61K | 1.28M | 691.07K | 445.82K | 560.00K | 530.07K | 494.25K | 703.06K | 1.19M | 985.42K | 886.05K | 572.87K | 966.80K | 668.39K | 443.78K | 346.67K | 228.62K | 3.80M | 1.60M | 900.00K |
| General & Administrative | 6.53M | 5.00M | 4.22M | 3.54M | 3.74M | 3.61M | 3.93M | 3.13M | 2.87M | 1.85M | 1.79M | 2.25M | 2.24M | 2.96M | 2.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.48M | 1.55M | 858.06K | 632.55K | 651.46K | 556.41K | 464.91K | 517.02K | 602.23K | 656.99K | 893.58K | 1.52M | 1.39M | 1.47M | 1.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.01M | 6.56M | 5.07M | 4.17M | 4.40M | 4.17M | 4.39M | 3.65M | 3.47M | 2.50M | 2.68M | 3.77M | 3.64M | 4.43M | 4.35M | 4.46M | 3.02M | 2.68M | 1.81M | 1.51M | 1.43M | 1.26M | 1.20M | 1.24M | 1.50M | 2.60M | 1.20M |
| Other Expenses | 161.24K | 160.34K | 99.40K | 0.00 | 0.00 | 0.00 | -273.54K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 10.22M | 8.51M | 6.21M | 5.19M | 5.44M | 5.26M | 5.39M | 4.14M | 4.75M | 3.19M | 3.09M | 4.33M | 4.63M | 5.39M | 5.93M | 6.00M | 4.27M | 3.81M | 2.55M | 2.63M | 2.25M | 1.86M | 1.73M | 1.67M | 5.60M | 4.50M | 2.30M |
| Cost & Expenses | 19.25M | 16.47M | 13.76M | 11.05M | 12.30M | 12.40M | 10.76M | 8.68M | 7.78M | 7.08M | 6.83M | 8.25M | 7.87M | 8.11M | 8.45M | 8.48M | 6.39M | 5.56M | 4.23M | 4.12M | 3.27M | 2.70M | 2.68M | 2.25M | 6.20M | 5.10M | 2.80M |
| Interest Income | 457.74K | 82.27K | 66.00 | 1.06M | 1.07M | 172.00 | 22.00 | 616.00 | 2.79K | 9.81K | 9.16K | 159.00 | 3.50K | 2.00K | 46.14K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 839.38K | 826.56K | 1.60M | 1.06M | 1.07M | 852.03K | 924.61K | 691.25K | 745.22K | 850.88K | 718.78K | 1.06M | 976.03K | 889.68K | 161.59K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.16M | 1.04M | 822.04K | 690.09K | 568.82K | 690.08K | 510.16K | 413.68K | 418.42K | 403.26K | 419.20K | 431.23K | 460.76K | 457.09K | 410.49K | 355.71K | 273.39K | 242.64K | 166.59K | 154.08K | 153.92K | 160.52K | 180.25K | 207.36K | 300.00K | 300.00K | 200.00K |
| EBITDA | 1.96M | 3.33M | 5.39M | -95.44K | 1.54M | -7.08M | -2.80M | 1.25M | 1.51M | 1.73M | 1.31M | -1.25M | -1.08M | -1.19M | -1.31M | -3.13M | -2.07M | -1.68M | 317.60K | 101.14K | -272.42K | 266.86K | 493.44K | -186.30K | -4.40M | -1.90M | 100.00K |
| EBITDA Ratio | 11.85% | 19.55% | 30.43% | 1.57% | 12.52% | 6.39% | -3.32% | 13.17% | 17.05% | 20.60% | 15.51% | -17.17% | -18.90% | -18.47% | -21.60% | -62.77% | -51.07% | -45.97% | 7.26% | 2.49% | -9.57% | 9.51% | 16.51% | -10.03% | -268.75% | -54.84% | 3.70% |
| Operating Income | -2.74M | 2.69M | 4.84M | -524.60K | 1.11M | -742.81K | -1.50M | 148.41K | 348.98K | 475.62K | 168.18K | -1.58M | -1.64M | -1.65M | -1.72M | -3.49M | -2.34M | -1.92M | 151.02K | -52.95K | -426.33K | 106.34K | 313.18K | -393.66K | -4.60M | -2.00M | -100.00K |
| Operating Income Ratio | -16.57% | 14.11% | 26.01% | -4.98% | 8.27% | -5.94% | -14.72% | 1.56% | 3.93% | 5.66% | 2.22% | -23.63% | -26.35% | -25.54% | -28.35% | -69.89% | -57.83% | -52.63% | 3.45% | -1.30% | -14.98% | 3.79% | 10.48% | -21.20% | -287.50% | -64.52% | -3.70% |
| Total Other Income/Expenses | 2.70M | -744.29K | -1.60M | -4.13M | -1.07M | -7.88M | -2.73M | -689.61K | -742.44K | -752.12K | 311.81K | -812.73K | -1.02M | -887.68K | 0.00 | 0.00 | -370.57K | -174.11K | 62.51K | 153.76K | 112.50K | 18.57K | 31.16K | 20.08K | 0.00 | 100.00K | 100.00K |
| Income Before Tax | -39.48K | 1.87M | 3.23M | -4.66M | 43.68K | -8.62M | -4.23M | 148.41K | 348.98K | 475.62K | 168.18K | -2.64M | -2.61M | -2.54M | 0.00 | 0.00 | -2.71M | -2.09M | 213.53K | 97.06K | -313.83K | 124.91K | 344.35K | -373.58K | 0.00 | -1.90M | 0.00 |
| Income Before Tax Ratio | -0.24% | 9.78% | 17.39% | -44.27% | 0.33% | -68.91% | -41.53% | 1.56% | 3.93% | 5.66% | 2.22% | -39.53% | -41.97% | -39.28% | 0.00% | 0.00% | -66.98% | -57.41% | 4.88% | 2.39% | -11.02% | 4.45% | 11.52% | -20.12% | 0.00% | -61.29% | 0.00% |
| Income Tax Expense | 0.00 | 77.23K | 1.60M | 1.57M | 11.76K | 852.03K | -450.00K | -600.00K | -265.00K | 306.65K | 166.80K | 159.00 | 3.50K | 887.68K | 759.98K | 177.83K | 0.00 | 211.61K | 88.00K | 82.79K | 49.88K | 55.40K | 103.23K | 76.65K | 100.00K | 200.00K | 100.00K |
| Net Income | -39.48K | 1.79M | 1.63M | -6.23M | 31.92K | -8.62M | -3.78M | 748.41K | 613.98K | 168.98K | 1.38K | -2.64M | -2.61M | -2.54M | -2.48M | -3.67M | -2.71M | -2.09M | 125.53K | 14.27K | -363.71K | 69.51K | 241.12K | -450.23K | -4.70M | -2.10M | -100.00K |
| Net Income Ratio | -0.24% | 9.38% | 8.77% | -59.17% | 0.24% | -68.91% | -37.11% | 7.86% | 6.92% | 2.01% | 0.02% | -39.53% | -41.97% | -39.28% | -40.85% | -73.45% | -66.98% | -57.41% | 2.87% | 0.35% | -12.78% | 2.48% | 8.07% | -24.25% | -293.75% | -67.74% | -3.70% |
| EPS | 0.00 | 0.01 | 0.01 | -0.06 | 0.00 | -0.09 | -0.04 | 0.01 | 0.01 | 0.00 | 0.00 | -0.04 | -0.05 | -0.05 | -0.05 | -0.08 | -0.07 | -0.06 | 0.00 | 0.00 | -0.01 | 0.00 | 0.01 | -0.01 | -0.14 | -0.06 | 0.00 |
| EPS Diluted | 0.00 | 0.01 | 0.01 | -0.06 | 0.00 | -0.09 | -0.04 | 0.01 | 0.01 | 0.00 | 0.00 | -0.04 | -0.05 | -0.05 | -0.05 | -0.08 | -0.07 | -0.06 | 0.00 | 0.00 | -0.01 | 0.00 | 0.01 | -0.01 | -0.14 | -0.06 | 0.00 |
| Weighted Avg Shares Out | 138.05M | 135.38M | 114.85M | 104.84M | 96.97M | 95.80M | 84.70M | 84.66M | 80.87M | 68.98M | 66.60M | 61.93M | 54.84M | 48.63M | 46.45M | 45.85M | 38.74M | 34.87M | 34.91M | 34.50M | 36.37M | 34.48M | 34.48M | 34.37M | 33.57M | 35.00M | 32.32M |
| Weighted Avg Shares Out (Dil) | 137.91M | 141.69M | 141.68M | 104.84M | 97.09M | 96.20M | 84.70M | 84.71M | 82.15M | 72.23M | 66.60M | 61.93M | 54.84M | 48.63M | 46.45M | 45.85M | 38.74M | 34.87M | 34.91M | 34.50M | 36.37M | 34.48M | 34.48M | 34.37M | 33.57M | 35.00M | 32.32M |
Microbix Reports Strong Results for Q2 Fiscal 2024
MISSISSAUGA, Ontario, May 15, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its second quarter and first half of fiscal 2024 ended March 31, 2024 (“Q2”...
Microbix Schedules Release of Results for Q2 Fiscal 2024
Results Release and Webinar Discussion on Morning of May 15, 2024 MISSISSAUGA, Ontario, May 08, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file...
Microbix Presenting at the 2024 Bloom Burton Conference
MISSISSAUGA, Ontario, April 11, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces it will be attending and presenting at the Bloom Burton & Co. Healthcare Investor Conference (the...
Microbix Announces Annual and Special Meeting Voting Results
MISSISSAUGA, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF) (“Microbix®” or the Company”), a life sciences innovator and exporter, announces the voting results from the Annual and Special Meeting of Shareholders of the Company...
Microbix's Clot-Buster Drug Project Advances
Sequel Pharma Executes Agreement with CDMO for Drug Substance Production Sequel Pharma Executes Agreement with CDMO for Drug Substance Production
Microbix Unveils Test Controls for Head and Neck Cancer
HPV-related Tissue-Sample Mimics for QC of histology and PCR analyses HPV-related Tissue-Sample Mimics for QC of histology and PCR analyses
Microbix Announces Issuance of Stock Options
MISSISSAUGA, Ontario, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer and exporter, announces the issuance of stock options under its shareholder-approved 2018 stock option plan (the “Stock Option Plan”),...
Microbix Biosystems Inc. (MBXBF) Q1 2024 Earnings Call Transcript
Microbix Biosystems Inc. (MBXBF) Q1 2024 Earnings Call Transcript
Microbix Reports Record Results for Q1 Fiscal 2024
Record Revenues of $8.4 million and Record Net Income of $2.5 million Record Revenues of $8.4 million and Record Net Income of $2.5 million
Microbix Schedules Release of Results for Q1 Fiscal 2024
Results Release and Webinar Discussion on Morning of February 14, 2024 Results Release and Webinar Discussion on Morning of February 14, 2024
Source: https://incomestatements.info
Category: Stock Reports